Christopher Morrison
In a bold move it says will bolster its late-stage pipeline and provide necessary scale in sales and biologics manufacturing,...
Schering-Plough Adds to Pipeline with Organon Acquisition
In a bold move it says will bolster its late-stage pipeline and provide necessary scale in sales and biologics manufacturing, Schering-Plough Corp. is acquiring the CNS and women's health specialist Organon BioSciences from Dutch conglomerate Akzo Nobel for $14.4 billion. For the acquisition to be a success, SP will have to find value where others have not--specifically in Organon's Phase III schizophrenia treatment asenapine, which was handed back to the company by Pfizer after disappoinging clinical results.
More from Business Strategy
• By
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
• By
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
• By
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
• By
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
More from In Vivo
• By
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
• By
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
• By
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.